Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Redhill BiopharmaSTU:2RH 18 3-Year EBITDA Growth Rate is 81.10% as of Dec. 2025, which is 889% above its 10-year median of 8.20. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 810 Drug Manufacturers companies, Redhill Biopharma ranks better than 95.93% on this metric.
During the past 12 months, Redhill Biopharma's average EBITDA Per Share Growth Rate was -391.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 81.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Redhill Biopharma was 81.10% per year. The lowest was -72.90% per year. And the median was 8.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Redhill Biopharma 3-Year EBITDA Growth Rate Related Terms
STU:2RH vs CTTH, SBFM, AKAN: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redhill Biopharma 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Redhill Biopharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 81.10% mean?
Redhill Biopharma (STU:2RH) has a 3-Year EBITDA Growth Rate of 81.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Redhill Biopharma and its competitors. This is 889% above median its historical median of 8.20. According to the industry distribution chart, Redhill Biopharma ranks #33 out of 810 companies in the Drug Manufacturers industry, placing it in the top 4.1%.
Is Redhill Biopharma's 3-Year EBITDA Growth Rate too high?
Redhill Biopharma's current 3-Year EBITDA Growth Rate of 81.10% is 889% above median its 10-year median of 8.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Redhill Biopharma's value of 81.10% is 811.2% above this industry median. Based on the distribution chart, Redhill Biopharma ranks #33 out of 810 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's 3-Year EBITDA Growth Rate compare to CTTH and SBFM?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #33 out of 810 companies for 3-Year EBITDA Growth Rate. This places Redhill Biopharma in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Redhill Biopharma's value of 81.10% is 811.2% above this benchmark. While the company's 10-year median is 8.20 vs. the industry median of 8.90, Redhill Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Redhill Biopharma's current 3-Year EBITDA Growth Rate of 81.10% is 811.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Redhill Biopharma and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redhill Biopharma's current 3-Year EBITDA Growth Rate is 81.10%, which is 889% above median its own 10-year median of 8.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current 3-Year EBITDA Growth Rate of 81.10%. The current 3-Year EBITDA Growth Rate is 81.10%, which is 889% above median its 10-year median of 8.20 and 811.2% above the Drug Manufacturers industry median of 8.90. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current 3-Year EBITDA Growth Rate is 81.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score
Get the complete analysis for STU:2RH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RH has been successfully added to your 
